The role of commanders in Mongol campaigns
Is this your thesis?
This record came from a bulk archive import. If it’s yours, link it to your profile.
Abstract (EN)
This study is a compilation created with the aim of examining the commanders who made the Mongol Empire, which left its mark on history under the leadership of Genghis Khan in the 13th century, successful in its campaigns. The purpose of this study is to examine the role of the commanders who served in the Mongol Empire during the campaigns and to identify and interpret the reasons for their actions based on the necessary information. Accordingly, the military structure of the Mongol Empire will first be discussed, followed by information about the campaigns and a discussion of the reasons for the commanders' actions. The sources used throughout the study consist of works from the period in which they were written to the present day, and in addition to the original Turkish and English sources, there are Turkish and English translations of Persian, Russian, and Chinese sources from the period. Keywords: Mongol Empire, Mongol Army System, Mongol Commanders, Noyans, Genghis Khan, Subutai, Jebe.
Author
Emre İnan Karahan
How to Cite
Emre İnan Karahan (Master Thesis). The role of commanders in Mongol campaigns, 2025, Yeditepe University.
Keywords
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Yeditepe University
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)